Jerusalem, 17 December, 2025 (TPS-IL) — Amorphical, an Israeli biotech specializing in nano-amorphous mineral therapeutics, announced positive final long-term results from its Phase 2 trial of nano-amorphous Calcium Carbonate (ACC) for moderate-to-severe Crohn’s disease. Conducted at the Soroka University Medical Center in Beer-Sheva, the study confirmed meaningful clinical improvements and sustained remission up to 48 weeks post-baseline.
The therapy, designed to locally neutralize acidity and deliver bioavailable calcium without immunosuppression, showed a favorable safety profile and significant symptom reduction compared with placebo. Amorphical plans to advance ACC into further clinical development and engage with investors to support a full Phase 2 FDA program.